Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer

NCT02254785 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Castration-Resistant Prostatic Cancer

Interventions

DRUG: cabazitaxel
DRUG: Abiraterone
DRUG: Enzalutamide 160mg daily (oral)

Sponsor

British Columbia Cancer Agency

Collaborators

[object Object]
[object Object]